INTRODUCTION {#sec0005}
============

Alzheimer's disease (AD) is an incurable neurodegenerative disorder, affecting 6% of the population over the age of 65 and a total of 35 million patients in the world as of 2010 \[[@ref001]\]. Pathologically, it is primarily characterized by the appearance of both amyloid-β (Aβ) aggregates and neurofibrillary tangles (NFT), accompanied by a progressive loss of neurons in the cortex. Two primary forms of AD are known: familiar (fAD, or early-onset), and sporadic (sAD, or late-onset), the latter of which comprises 95--99% of all AD cases \[[@ref002]\]. fAD is an autosomal dominant inherited form of the disease that most often results from mutations in one of the three genes amyloid precursor protein (*APP*) \[[@ref004]\], presenilin 1 (*PSEN1*) \[[@ref006]\], and presenilin 2 (*PSEN2*) \[[@ref007]\]. Despite the high heritability rates for sAD (79%) \[[@ref008]\], robust genetic components underlying the emergence of sAD have remained elusive. Although the etiology of sAD and fAD differs, both forms of AD share the same clinical picture, although fAD has an earlier age of onset.

In addition to neurons, glia cells have a central role in brain physiology in health and disease, by maintaining homeostasis in the brain. In AD, several glial cell processes are affected. Astrocytes and microglia mediate chronic neuroinflammation and oxidative stress, contributing to the AD pathogenesis \[[@ref009]\]. In addition, activation of both astrocytes and microglia has been linked with the formation of Aβ aggregates \[[@ref010]\]. An important glial protein, myelin basic protein (MBP), integral to myelin formation by oligodendrocytes and Schwann cells, has been colocalized with Aβ in human AD brain and was increased in AD brains possibly by axonal damage \[[@ref012]\]. Moreover, MBP has been shown to interfere with Aβ fibrillation \[[@ref013]\]. Glial fibrillary acid protein (GFAP), a protein essential for astrogliosis, is also found to be upregulated in human AD brain tissue \[[@ref016]\]. In postmortem brains of sAD patients, oligodendrocyte-linked myelin deficits have been observed \[[@ref019]\]. More recently, alterations in myelination and oligodendrocyte status have been documented, even prior to tau and Aβ pathology, and have been discussed as an early therapeutic target \[[@ref020]\].

In a microarray screening of human hippocampal postmortem brain tissue from sAD patients and control samples, a gene exclusively expressed in glia cells, quaking (*QKI*) was among a group of differentially expressed genes, increasing in accordance with AD severity \[[@ref022]\]. In addition to sAD, *QKI* has also been associated with other neurological diseases such as schizophrenia \[[@ref023]\], glioblastoma, and ataxia (reviewed by Chenard et al. \[[@ref025]\]). QKI is a glial cell-expressed RNA binding protein \[[@ref026]\] and a member of the STAR (Signal Transduction and Activation of RNA) protein family. Animal studies have shown that QKI modulates splicing, export, and stability of RNA, as well as mRNA processing \[[@ref027]\]. Five isoforms of *QKI* have been identified, *QKI5, QKI6, QKI6B, QKI7,* and *QKI7B* \[[@ref028]\], with each transcript differing in their C-terminal amino acids \[[@ref029]\]. QKI5 is located in the nucleus, while QKI6 and QKI7 are primarily found in the cytoplasm \[[@ref025]\]. Early studies have identified a role for QKI in myelin formation \[[@ref030]\] which occurs by promoting oligodendroglia differentiation \[[@ref031]\], regulating the expression of *MBP* \[[@ref032]\], *GFAP* \[[@ref033]\] and the splicing of myelin-associated glycoprotein (*MAG*) \[[@ref034]\]. Recently, we showed that *QKI* is not only expressed in human oligodendroglia cells but also in astrocytes, indicating an involvement in regulating glia cell function \[[@ref033]\]. Thus, *QKI* could be of particular interest for studying diseases associated with glia cell and myelin dysfunction, including neurodegenerative diseases such as AD.

In this study, we aimed to further examine different isoforms of *QKI* in relation to sAD by quantifying gene expressions in the frontal cortex of human postmortem samples, followed by a linear regression to examine the relationship between *QKI* and other genes associated with the pathological hallmarks of sAD, i.e., *APP, PSEN1, PSEN2,* and *MAPT*.

MATERIALS AND METHODS {#sec0010}
=====================

Postmortem brain tissue samples {#sec0015}
-------------------------------

Postmortem human brain samples (*n* = 123) were provided by the Maudsley Brain Bank (Department of Neuropathology, Institute of Psychiatry, King's College, London, United Kingdom). The samples consisted of tissue from the frontal cortex, specifically Brodmann areas 8 and 9. In the cohort, 62 samples were taken from patients diagnosed with sAD (consisting of 31 females and 31 males) and 61 from individuals without any psychiatric disorder (consisting of 30 females and 31 males). All patients were CERAD-positive.

RNA and mRNA purification {#sec0020}
-------------------------

Each autopsy sample was divided into 50--100 mg of tissue and homogenized in 2 ml of TRIzol reagent (Life Technologies) using an Ultra-Turrax T25 basic homogenizer (IKA Laboratory Equipment). The samples were stored at --70°C prior to use. RNA extraction from the homogenized sample was performed by phenol-chloroform extraction. The mRNA was subsequently isolated with magnetic beads (PolyATtract mRNA Isolation Systems, Promega), as described previously \[[@ref035]\]. The total quantity of RNA and mRNA was measured with RiboGreen, RNA Quantification Reagent kit (Molecular Probes). The samples were concentrated using Microcon-30kDa Centrifugal Filter (Millipore Corporation). RNA quality was assessed by gel electrophoresis.

Real-time RT-PCR {#sec0025}
----------------

Two replicate mRNA samples (10 μg RNA per sample) were reverse transcribed from each of the 123 individuals (SuperScript Reverse Transcriptase, Life Technologies). The cDNA from each sample was individually placed into a single well of an optical 96-well reaction plate (Applied Biosystems), and was subsequently diluted at a ratio of 1:20. Replica plates were produced, dried, and then stored at 4°C. A set of three 96-well plates (sample sets) were used for each gene measurement, covering the total duplicates of 62 sAD patients and 61 controls, a standard curve and negative control samples.

For each well of cDNA in the 96-well replica plates, 16 μl of TaqMan Universal master mix (Thermo Fisher Scientific) was added to each cDNA sample dissolved in 4 μl RNase-free water. Gene expression measurements (Applied Biosystems 7500 Real-Time PCR System, Thermo Fisher Scientific) were conducted according to standard protocol: 50°C for 2 min (Uracil-N-glycosylase incubation) and 95°C for 10 min (AmpliTaq Gold Activation), followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Expression data were collected from the ABI 7500 software, in which expression for each gene was quantified using a standard curve. Primers and probes for *APP* (Hs00169098_m1), *PSEN1* (Hs00240518_m1), *PSEN2* (Hs00240982_m1), and *MAPT* (Hs00213491_m1) were ordered from Applied Biosystems as Assay-on-Demand (TaqMan Gene Expression Assay, Thermo Fisher Scientific), while primers for the control genes beta-actin (*ACTB*), glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*), and *QKI* pan (primers detecting all *QKI* isoforms), *QKI5, QKI5* and *QKI7* were designed in Primer Express Software (Thermo Fisher Scientific). Gene specific primer sets were as follows for *ACTB,* 5'-GAGCTACGAGCTGCCTGACG -3' and 5'-GTAGTTTCGTGGATGCCACAGGACT-3'; *GAPDH,* 5'-AGCTCACTGGATGGCCTT-3' and 5'-TTCTAGACGGCAGGTCAGGTC-3'; *QKI* pan, 5'-GCACCTACAGAGATGCCAACATTA-3' and 5'-CTGGGCTGTTGCTGCAAGA-3'; *QKI5,* 5'-AATCCTTGAGTATCCTATTGAACCTAGT-3' and 5'-GCATATCGTGCCTTCGAACTTT-3'; *QKI6,* 5'-AGCTACATCAATCCTTGAGTATCCTATTG-3' and 5'-TAGCCTTTCGTTGGGAAAGC-3'; *QKI7,* 5'-GCTACATCAATCCTTGAGTATCCTATTG-3' and 5'-CAGGCATGACTGGCATTTCA-3'.

Statistical analysis {#sec0030}
--------------------

In total, 246 sample measurements were made from all three plates. There were 7, 27, 10, and 7 missing data points for *QKI* pan, *QKI5, QKI6,* and *QKI7,* respectively. As the data collection was performed with duplicates, few samples were missing entirely (3 sAD and 2 Control samples from *QKI5* measurements, and 1 sAD sample from *QKI7*). Additionally, we implemented an expectation-maximization algorithm to model the missing data points, as it has been shown that non-detects in qPCR data are not likely to be missing at random, and that conventional approaches to handling non-detects can lead to bias \[[@ref036]\]. The missing data values were thus inferred from a likelihood of values, given the distribution of the data. The algorithm produced iterative steps of expectations of the missing values, and produced a maximum likelihood estimate of the underlying data. This was performed until convergence, and the data were accepted. The data were then base-10 log-transformed before further analysis.

An analysis of covariance (ANCOVA) model was used to determine if the detected mRNA expression for *QKI* pan, *QKI5, QKI6,* and *QKI7* was significantly related to (or affected by) the status of the brain sample. The model included the factors of disease status (i.e., AD or control), sex, qPCR plate, and the covariates of age at death, time postmortem, and the geometric mean of mRNA levels of *ACTB* and *GAPDH* (reference genes). Estimated marginal means from the model were used in the calculation of fold change differences. The mRNA level of genes associated with the emergence of AD were also measured and tested with the model, specifically measurements of *APP* (of which the data has previously been shown by our group \[[@ref037]\]), *PSEN1, PSEN2,* associated with fAD \[[@ref036]\]; and *MAPT,* associated with sAD \[[@ref033]\]. Residuals were normally distributed, as assessed by the Shapiro-Wilks test and visual inspection of Q-Q plots. There was independence of errors, examined with the Durbin-Watson test. There was homogeneity of regression slopes, as the interaction term was not significant. Bonferroni corrections were applied to counteract multiple testings.

A multiple linear regression was used to determine if changes in the expression of *APP, PSEN1, PSEN2,* or *MAPT* could be predicted by variation of total *QKI* or *QKI* isoforms. As each *QKI* isoform was highly correlated with the *QKI* pan probe (*r* \> 0.69, for both *QKI5* and *QKI6, r* \> 0.85 for *QKI7*), each was regressed onto *QKI* pan to form the residual expression, to provide the differences between each isoform and the general *QKI* expression level. The residuals are orthogonal to *QKI,* and represent relative differences to general *QKI* levels. These values are therefore more indicative of each individual isoform's expression. The multiple linear regression was firstly fitted with the geometric mean of the reference gene values, to account for the general mRNA expression within the sample. Following this, the total *QKI* pan values were entered into the model, and each of the three isoform residuals were entered as explanatory variables in separate equations.

In addition, a correlation-based Principal Component Analysis (PCA) was performed on the gene expression values of *APP, PSEN1,* and *PSEN2,* reducing the data of these three genes to a single component \[[@ref038]\]. A single component was formed due to the close alignment of variance predicted by *QKI* and *QKI* isoforms (see [Table 1](#jad-53-jad160160-t001){ref-type="table"}), and their shared involvement in parts of the Aβ pathway. The principal component also accounted for 94% of the variance of the data from these three genes, which is highly representative of the shared gene expression. The component (PC1) was used as above, in a linear regression with each *QKI* isoform residual. The PC1 data were first regressed onto the geometric mean of the reference gene values, to largely remove the influence of general mRNA expression, and the subsequent residuals from this were used as normalized values. The data were also split into control and sAD patients to explore the specificity of the AD gene outcome for each group in relation to the *QKI* isoforms. The data therefore show the predictive value of each *QKI* isoform to a sAD-related gene value, within the context of disease state (i.e., sAD or control). All statistical tests were performed using IBM SPSS version 21 \[[@ref039]\].

Quaking response element detection {#sec0035}
----------------------------------

QKI is known to selectively bind to sequences harboring a QKI Response Element (QRE); at which point RNA splicing, export stabilizing, and mRNA processing are proposed to occur. Galarneau and Richard \[[@ref040]\] defined a probability matrix of the QRE, which we used in searching the known RefSeq RNA transcript variant sequences of *APP, PSEN1, PSEN2,* and *MAPT* (accession numbers are shown in [Supplementary Table 1](#S1){ref-type="supplementary-material"}). Sequences were first retrieved from GenBank and searched via the FUZZNUC tool (EMBOSS 6.5.0 \[[@ref041]\]). The sequences were then searched for the QRE as defined by Galarneau and Richard \[[@ref040]\], consisting of the nucleotides NACUAAY-N~1--20~-UAAY (where N refers to any nucleotide, and Y refers to cytosine or thymine), with mismatches that were verified with the matrix and other potential QREs identified previously \[[@ref040]\].

RESULTS {#sec0040}
=======

Gene expression of QKI and QKI isoforms is upregulated in sAD {#sec0045}
-------------------------------------------------------------

Gene expression levels of total *QKI* pan as well as its isoforms *QKI5*, *QKI6*, and *QKI7* were measured in 62 postmortem brain samples from sAD patients and compared to 61 control samples ([Fig. 1](#jad-53-jad160160-g001){ref-type="fig"}). In sAD, *QKI* and *QKI* isoforms were significantly upregulated. *APP* did not show any significant differences (*p* = 0.394), and while *PSEN1* showed a tendency to upregulation, this did not reach significance (*p* = 0.054). Additionally, *PSEN2* (*p* = 0.475), and *MAPT* (*p* = 0.144) expression values were not found to be significant, relative to control samples ([Fig. 2](#jad-53-jad160160-g002){ref-type="fig"}). Analysis after Bonferroni corrections showed that *QKI* pan was significantly different (*p* \< 0.005) with a 1.14-fold upregulation, *QKI5* (*p* \< 0.05) with a 1.08-fold upregulation, *QKI6* (*p* \< 0.05) with a 1.08-fold upregulation and *QKI7* (*p* \< 0.0005) with a 1.08-fold upregulation (all fold differences based on estimated marginal means from the ANCOVA model).

QKI expression is not correlated with increased age in either AD or control samples {#sec0050}
-----------------------------------------------------------------------------------

As age is the main risk factor for sAD, we decided to investigate whether the expression of *QKI* pan and its isoforms differed across sample age. Within the ANCOVA model above, age was not found to be a significant predictor of gene expression for *QKI* pan or any of the *QKI* isoforms (data not shown). This held true within both groupings of sAD and control samples, across replicate PCR plate, and across the sex of the sample.

Association of QKI and QKI isoforms with AD-associated genes {#sec0055}
------------------------------------------------------------

The main pathological hallmarks of both fAD and sAD are the presence of Aβ plaques and NFT. Aβ plaques have been associated with mutations in *APP, PSEN1,* and *PSEN2*, and tauopathy to *MAPT* \[[@ref043]\]. When we evaluated these genes in human postmortem brain samples, no alterations in gene expression were found for *APP* (as previously shown by Emilsson et al. \[[@ref037]\]), *PSEN1, PSEN2,* or *MAPT.* To evaluate whether *QKI* and *QKI*transcripts are predictive of the variation of *APP, PSEN1, PSEN2,* and *MAPT,* we implemented a multiple linear regression. The AD-related gene expression was entered as dependent variables, while *QKI* pan probe expression and each *QKI* isoform was entered as an independent variable. We found that the expression level of *QKI* pan was the greatest predictor of AD-related gene expression ([Table 1](#jad-53-jad160160-t001){ref-type="table"}), significant for all genes, and accounting for between 23% and 36% of the variation. As each isoform was the second independent variable in the multiple linear regression, any further variation explained by the isoforms is in addition to the variation explained by *QKI* pan. *QKI5* was a significant predictor of the expression of all AD related genes, accounting for 2--6% of variation. *QKI6* was a significant predictor of *APP*, *PSEN1,* and *PSEN2,* and accounted for 3--4% of the variation. No significant relation was found with *MAPT* and *QKI6. QKI7* was also predictive of *APP, PSEN1,* and *PSEN2,* accounting for 3--5% of expression, but was not predictive of *MAPT* ([Table 1](#jad-53-jad160160-t001){ref-type="table"}).

A PCA was also performed in order to examine the co-varying expression of the three AD-associated genes involved in the amyloid pathway. The principal component accounted for 94% of the variance of *APP, PSEN1,* and *PSEN2*. This principle component was, following normalization to the geometric mean of the reference genes, used in a multiple linear regression as above, with *QKI* pan and *QKI* isoforms. *QKI* pan ([Fig. 3](#jad-53-jad160160-g003){ref-type="fig"}) and all *QKI* isoforms were significant predictors of the PC1 variance ([Table 1](#jad-53-jad160160-t001){ref-type="table"}).

Subsequently, we extended our investigation and split the data according to sample status (sAD or ctrl) and repeated the multiple regression as before. *QKI* pan appeared to be a stronger predictor of PC1 within control samples ([Supplementary Table 2](#S1){ref-type="supplementary-material"}). No striking differences emerged for the *QKI* isoforms, although *QKI5* and *QKI7* appeared to predict more variance of *PSEN2* within control samples, similar to *QKI* pan.

APP, PSEN1, and MAPT harbor a putative QRE {#sec0060}
------------------------------------------

We investigated if any of the AD-related genes in this study contained QREs. The QRE is the location at which RNA splicing, export, stabilizing, and mRNA processing are proposed to occur upon QKI binding. A QRE site was found within all ten transcript variants of *APP*, transcript variant two of *PSEN1*, and all eight transcript variants of *MAPT* ([Fig. 4](#jad-53-jad160160-g004){ref-type="fig"}). These sequences are based on either the identified consensus sequence or a sequence with partial nucleotide differences that were previously confirmed \[[@ref040]\].

In *APP* the QRE was found within the 17th exon, and consisted of 5'-[AATTAAT]{.ul}CCACACATCAG[TAAT]{.ul} -3' for all 10 transcripts. This sequence has partial, yet validated, differences to the consensus sequence NACUAAY-N~1--20~-UAAY (where N refers to any nucleotide, and Y refers to cytosine or thymine). The first underlined segment refers to the core QRE sequence and the second to the half-site \[[@ref040]\]. The QRE in *PSEN1* was found to be 5'-[TACTAAT]{.ul}GA[CAAT]{.ul}-3', with the first four nucleotides residing in exon 3, and the remaining residing in exon 4. The core sequence is identical to the consensus sequence, although the half-site shows a single nucleotide difference. Galarneau and Richard \[[@ref040]\] have previously shown that variations within the half-site are tolerable and may not even be necessary for QKI binding in some cases. The QRE in *MAPT* consisted of 5'-[TAAT]{.ul}TGGTTAAT[CACTTAA]{.ul}-3' for all transcript variants and was found in the 3'UTR. The first underlined segment refers to the half-site, and the second to the core QRE sequence. As with *APP*, this sequence has partial, yet previously validated differences to the consensus sequence. There has not yet been a quantification of the proportion of QREs within the human genome, yet previous research would suggest a prevalence of around 5--6% in mice using the less conservative QRE sequence, in which certain mismatches are tolerable (this figure is around 4% in mice using only the identified consensus) \[[@ref040]\].

DISCUSSION {#sec0065}
==========

In this study, we investigated the association of sAD with the expression of the *QKI* gene and three of its isoforms, *QKI5, QKI6,* and *QKI7,* in postmortem AD brain samples from the prefrontal cortex. The expression level of *QKI* was able to explain a large part of the variation of genes known for theirinvolvement in the pathological hallmarks of sAD, i.e., *APP, PSEN1, PSEN2,* and *MAPT.*

Consistent with previous findings from Gómez Ravetti et al. \[[@ref022]\], the *QKI* gene expression was upregulated in postmortem sAD brain samples from the prefrontal cortex. Furthermore, the *QKI* isoforms *QKI5, QKI6,* and *QKI7* were all upregulated in sAD samples. Gómez Ravetti et al. \[[@ref022]\] also showed that *QKI* expression increases with the severity of AD status. While analysis from Feng et al. \[[@ref044]\] suggests that *QKI* may have expression differences in early, but not late stages of AD. Unfortunately, we did not have any data on the disease severity, or time of onset, in our patient material; therefore, we were not able to investigate these factors in relation to gene expression. However, in our analysis, *QKI* and *QKI* isoform upregulation was not significantly associated with differences in age. We therefore suggest that *QKI* upregulation in AD is not age-dependent and could indeed be a molecular biomarker of AD, as previously suggested \[[@ref022]\].

It is known that *QKI* is exclusively expressed in glial cells in the mature brain \[[@ref026]\]; therefore, any potential effects of upregulated *QKI* on sAD progression must occur via an altered glial cell environment or function. With identified gene expression in astrocytes, oligodendrocytes, and Schwann cells, *QKI* alterations could affect both synaptic function\[[@ref045]\] and myelin maintenance \[[@ref021]\].

AD progression has been suggested to switch astrocytes from a neuroprotective state to reactive gliosis \[[@ref047]\], preventing axonal outgrowth \[[@ref047]\] and reducing neuronal inhibition \[[@ref048]\]. Such defective inhibition is linked to the destabilization of neuronal networks in response to Aβ \[[@ref049]\]. Astrocytes have been shown to accumulate toxic Aβ, and subsequent lysis of the astrocytes containing Aβ can cause the deposition of Aβ plaques \[[@ref050]\], which could further destabilize neuronal networks. Additionally, reactive astrogliosis has been linked to disrupted synaptic connectivity in a mouse strain carrying the human form of apolipoprotein E4, a protein linked to sAD \[[@ref051]\]. It has also been shown that *GFAP*, a gene regulated by *QKI* \[[@ref033]\], and associated with astrocytic activation, is upregulated in AD \[[@ref016]\]. Both astrocytic density and expression levels of *GFAP* correspond to Braak stage severity \[[@ref054]\], which suggests a link between astrocytosis and AD severity \[[@ref055]\].

In relation to myelin and AD, it has been shown that disturbed myelination is associated with AD \[[@ref019]\]. As oligodendrocytes are primarily responsible for myelination, their cell death would affectneuronal myelination maintenance \[[@ref057]\]. Aβ has been found in abundance within the white matter of AD patients \[[@ref059]\] and is found to be toxic to oligodendrocytes \[[@ref061]\]. *QKI* upregulation could therefore represent a compensatory reaction to Aβ toxicity in oligodendrocytes.

In addition to the upregulation of *QKI* and *QKI* isoforms in postmortem AD human brain samples, we also found that these expression values were associated with genes (*APP, PSEN1, PSEN2,* and *MAPT*) related to the pathological hallmarks of AD \[[@ref019]\]. *PSEN1* and *PSEN2* are part of the gamma secretase complex that cleaves AβPP and ultimately gives rise to the formation of Aβ plaques. *MAPT* encodes for the tau protein which, once phosphorylated, contributes to the formation of NFT. Analysis of samples separated by disease status revealed that the association appeared more pronounced in control samples ([Supplementary Table 2](#S1){ref-type="supplementary-material"}). Genetic dysregulation upon disease emergence has previously been found for a large number of genes within AD samples \[[@ref044]\], which could suggest that the lower amount of variance of AD-related gene expression predicted by *QKI* in sAD samples is a result of dysregulation brought on by AD pathology. In contrast, the variance of AD-related genes predicted by *QKI* in control samples could reflect normal regulation of these genes. So far, very little is known about the functions of the different *QKI* isoforms. It is therefore unclear whether the upregulation of *QKI* and its isoforms in sAD contributes to the emergence of the disease, if this is a secondary effect due to other causative mechanisms, or some combination thereof.

The gene expression data of the AD-related genes follow the trend of previously published findings, but in general, published expression data from human studies have shown varying results depending on splice variants examined, methods of measurement, and brain regions studied, so it is challenging to compare our data with previous reports. From previous studies of *APP* mRNA expression in human brain, the results have been inconclusive. Tanaka et al. analyzed several brain regions and found that in the frontal cortex, two of the three *APP* splice variants analyzed were upregulated in AD patient brains, while no differences were found in other regions \[[@ref062]\]. Golde et al. showed that *APP* splice variants in AD brains were elevated in the frontal white matter \[[@ref063]\], but the data varied in the frontal grey matter \[[@ref063]\]. In our study, *PSEN1* was not found to be significantly different in AD samples; however, elevated *PSEN1* mRNA levels in the superior frontal gyrus of AD patients has been found by Borghi et al. \[[@ref064]\]. Johnston and coworkers, on the other hand, failed to find differences in *PSEN1* expression in mid-temporal or superior frontal cortices from AD and control patients \[[@ref065]\], and Isoe-Wada et al. detected reduced *PSEN1* mRNA in the frontotemporal lobe of AD patients \[[@ref066]\]. We did not find a significant difference in the expression of *PSEN2* while another study has shown downregulation in hippocampus, frontal cortex, and basal forebrain in AD brains \[[@ref067]\]. While our results are therefore not indicative of any significant expression differences of *APP, PSEN1, PSEN2,* or *MAPT* in AD patients, this is not unexpected given inconsistent findings from priorstudies.

As QKI can regulate transcripts containing a QRE \[[@ref040]\], it is suggested that *QKI* upregulation could contribute to the emergence of sAD through interaction with *APP, PSEN1,* and *MAPT,* all of which harbor a putative QRE ([Fig. 4](#jad-53-jad160160-g004){ref-type="fig"}). Previous *in vitro* findings from our group showed that *QKI7* likely regulates the transcript expression of *GFAP* via the QRE \[[@ref033]\]. The association of *QKI* and *QKI* isoforms with AD-related genes may therefore represent a regulatory involvement. It has also been shown that QKI7 can induce apoptosis of oligodendrocytes \[[@ref068]\]. Mouse studies with abnormal *QK* and knocked-out *p53* showed that both genes were important for the maintenance and survival of neurons \[[@ref069]\]. These findings indicate a role of *QKI* in cell apoptosis in both glial cells and neurons, central to AD pathology \[[@ref070]\]. However, any connection between *QKI* expression and AD-related genes is currently speculative. Further research examining potential interactions could clarify whether or not the aforementioned processes are involved in AD pathogenesis.

Additionally, there has not yet been a comprehensive search of the prevalence of potential QRE sites within the human genome. However, of the approximately 25,000 genes within mice, 955 are found to contain a QRE site \[[@ref040]\], putting the proportion of QRE sites within the genome at around 4%. This proportion is increased with the inclusion of sequences with slight differences to the identified consensus sequence, to a total of 1,433 genes \[[@ref040]\]. This is equivalent to around 5--6% of genes containing QREs. While this is of course data from mice, it perhaps offers the best glimpse currently available at the prevalence of QRE sites.

It is however also possible that *QKI* upregulation is not directly linked to sAD emergence, but is rather a secondary effect. *QKI* has been shown to be directly regulated by *p53* \[[@ref072]\]. *p53*, most commonly known for its role in cancer progression, is activated in response to DNA damage \[[@ref073]\] (such as the result of oxidative stress \[[@ref074]\]), and can ultimately trigger apoptosis \[[@ref075]\]. Based on this, our finding that the expression of *QKI* and its isoforms are upregulated in sAD could be explained by increased stress-induced *p53* regulation. Additionally, as astrocytic activation is a well-documented response to many CNS injuries, including Alzheimer's disease \[[@ref022]\], the increase in *QKI* and *QKI* isoforms could represent a secondary process as a result of glial alteration.

In conclusion, we have found an upregulation of *QKI* and its isoforms (*QKI5, QKI6* and *QKI7*) in sAD patients compared to controls. This finding is consistent with previous research \[[@ref022]\]. We could also conclude that this upregulation is age-independent and that four AD-related genes, *APP, PSEN1, PSEN2,* and *MAPT,* were associated with the variance of *QKI* and *QKI* isoforms. Additionally, *APP, PSEN1,* and *MAPT* harbor a putative QRE site, suggesting a mechanism for regulation by QKI. How expression differences of *QKI* affect glial cell homeostasis and neuronal function in sAD is expected to be the result of complex genetic and proteomic alterations, which will require further deciphering through existing *QKI* animal models, including zebrafish and rodents \[[@ref030]\]. Our findings therefore provide a basis for further investigation into the mechanisms underlying the role of *QKI* in sAD formation and progression.
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![Scatterplots of gene expression values. sAD samples are shown in filled circles with solid line of best fit. Control samples are shown in open circles, with dashed line of best fit. Y-axis shows the target gene expression value. X-axis shows the geometric means of the reference genes (*ACTB* and *GAPDH*). All values are log10.](jad-53-jad160160-g001){#jad-53-jad160160-g001}

![Upregulated gene expression of *QKI,* and *QKI* isoforms in sAD postmortem brain samples. mRNA expression values (log10) are shown for *QKI* pan, *QKI* isoforms (*QKI5, QKI6, QKI7*) and AD associated genes (*APP, PSEN1, PSEN2, MAPT*), relative to control samples (zero line on the x-axis). Error bars indicate standard error and asterisks indicate significance level obtained from ANCOVA model (^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001).](jad-53-jad160160-g002){#jad-53-jad160160-g002}

![Scatterplot showing principal component (PC1) values of *APP, PSEN1,* and *PSEN2* gene expression, with values of PC1 predicted from *QKI* pan (standardized regression values). sAD samples are shown in filled circles with solid line of best fit. Control samples are shown in open circles, with dashed line of best fit. The distance between the circles and the line of best fit is representative of model accuracy, with shorter distances equating to a better fit.](jad-53-jad160160-g003){#jad-53-jad160160-g003}

![QRE (Quaking Response Element) shown within RNA sequences of *APP, PSEN1,* and *MAPT*. Numbers denote position within transcript variant 1 for each gene. For *APP* and *PSEN1,* the core QRE sequence and the half-site are shown as the first (from 5' to 3') and second underlined segment, respectively. The half-site is shown as the first (from 5' to 3') underlined segment for *MAPT,* and the second segment shows the core QRE sequence. Asterisks indicate that the sequence has a partial difference to the previously identified consensus sequence.](jad-53-jad160160-g004){#jad-53-jad160160-g004}

###### 

Variation of expression levels for each AD-related gene explained by *QKI* pan, and additional variation explained by *QKI5, QKI6,* and *QKI7* expression. Variation is listed as percentages. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001, ^\*\*\*\*^*p* \< 0.0001 and ns denote that *p* values were not significant

  Gene name      *QKI* pan       *QKI5*       *QKI6*    *QKI7*
  ----------- --------------- ------------ ------------ ------------
  *APP*        32%^\*\*\*\*^    3%^\*\*^    4%^\*\*\*^  5%^\*\*\*^
  *PSEN1*      36%^\*\*\*\*^     2%^\*^      3%^\*\*^   4%^\*\*\*^
  *PSEN2*      24%^\*\*\*\*^    4%^\*\*^     4%^\*\*^   3%^\*^
  *MAPT*       23%^\*\*\*\*^   6%^\*\*\*^     1% ns     2% ns
  PC1          32%^\*\*\*\*^    3%^\*\*^     4%^\*\*^   4%^\*\*^
